| 期刊簡介 | |||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | CURRENT MOLECULAR MEDICINE LetPub Score 5.2
50 ratings
Rate
Reputation 6.3 Influence 3.9 Speed 7.0 | ||||||||||||||||||||||||
| 期刊簡稱 | CURR MOL MED | ||||||||||||||||||||||||
| ISSN | 1566-5240 | ||||||||||||||||||||||||
| E-ISSN | 1875-5666 | ||||||||||||||||||||||||
| h-index | 93 | ||||||||||||||||||||||||
| CiteScore |
| ||||||||||||||||||||||||
| 自引率 (2023-2024) | 4.50%自引率趨勢 | ||||||||||||||||||||||||
| 掲載範囲 |
| ||||||||||||||||||||||||
| 官方網站 | http://benthamscience.com/journal/index.php?journalID=cmm | ||||||||||||||||||||||||
| 在線稿件提交 | http://bsp-cms.eurekaselect.com/index.php/CMM | ||||||||||||||||||||||||
| 開放訪問 | No | ||||||||||||||||||||||||
| 出版商 | Bentham Science Publishers B.V. | ||||||||||||||||||||||||
| 主題領域 | 医学 | ||||||||||||||||||||||||
| 出版國/地區 | NETHERLANDS | ||||||||||||||||||||||||
| 發行頻率 | 隔月刊行 | ||||||||||||||||||||||||
| 創刊年 | 2001 | ||||||||||||||||||||||||
| 每年文章數 | 98每年文章數趨勢 | ||||||||||||||||||||||||
| 黃金OA百分比 | 1.97% | ||||||||||||||||||||||||
| Web of Science 四分位 （ 2023-2024） | WOS Quartile: Q3
| ||||||||||||||||||||||||
| 索引 (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||||||||||
| 鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=1566-5240%5BISSN%5D | ||||||||||||||||||||||||
| 平均審稿時間 * | 來自出版商的數據: 來自作者的數據: Sort of slow, 4-8 Week(s) | ||||||||||||||||||||||||
| 競爭力 * | 來自作者的數據: Ordinary | ||||||||||||||||||||||||
| 參考鏈接 |
| ||||||||||||||||||||||||
| *所有的審稿過程指標，如接受率和審稿速度，僅限於用戶提交的稿件。因此，這些指標可能無法準確反映期刊的競爭力或速度。 | |||||||||||||||||||||||||
|
| |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
| [CURRENT MOLECULAR MEDICINE] 的評論 | 撰寫評論 |
| 作者: 东风妍歌 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2023-06-20 08:30:39 評論於 Review speed: 12.0 | Submission hit rate: 25.0 Experience sharing: Rejection given after more than 7 months, not recommended to submit for genetic family bioinformatics research in gastric cancer in SCI  (0) 讚！ | 东风妍歌  |
| 作者: 东风妍歌 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2022-09-22 13:06:35 評論於 Which direction does CURRENT MOLECULAR MEDICINE submit to, and what changes are now there, what is the situation? (0) 讚！ | 东风妍歌 |
| 作者: 韦陀依然 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2022-07-18 21:30:43 評論於 What's up now? (0) 讚！ | 韦陀依然 |
| 作者: 极乐贵斌 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2022-06-11 15:41:51 評論於 Review Speed: 12.0 | Submission Acceptance Rate: 50.0 Experience Sharing: The state change is still not seen (0) 讚！ | 极乐贵斌 |
| 作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-30 09:26:02 評論於 Due to the many factors that can affect the efficacy of animal experiments or clinical treatments, unless the results obtained significantly enhance the effectiveness beyond the sum of the efficacy of each drug, synergism can only be definitively confirmed. Otherwise, it is generally referred to as an additive effect (0) 讚！ | 维尔娜菲茨杰拉德 |
| 作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-30 08:20:23 評論於 ORCID is the Open Researcher and Contributor ID. ORCID ID is a unique and persistent academic identity for contributors, which distinguishes authors from other researchers and records all of the authors' relevant research activities. It is necessary to log in to each author's account and then link them in the account information modification section (0) 讚！ | 维尔娜菲茨杰拉德 |
| 作者: 北国博达 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-27 21:39:22 評論於 How to determine whether two drugs have a synergistic effect or an additive effect? (0) 讚！ | 北国博达 |
| 作者: Darlene Pepys 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-26 15:09:09 評論於 How to add ORCID iD if it was not provided when the article was published? (0) 讚！ | Darlene Pepys |
| 作者: 无冬海白 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2019-08-22 16:03:26 評論於 May I ask how long it has been since you last received any news? Is it good news or bad news? (0) 讚！ | 无冬海白 |
| 作者: 里贾纳奥斯卡 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2018-04-01 20:01:11 評論於 It has been over a year since I submitted the application, but there is still no news. What is going on? (0) 讚！ | 里贾纳奥斯卡 |
| 作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2017-07-18 12:46:58 評論於 The price keeps falling, will it drop below 2? It has dropped quite a bit in just a year, even 0.1 point should be cherished (0) 讚！ | 凌霄高洁 |
| 作者: 兴朝可爱吗 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2017-06-14 14:56:54 評論於 From first instance to receipt, 1 year and a half (0) 讚！ | 兴朝可爱吗 |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
Contact us
